Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084616 | 0.83 | HSD11B1 (0.37) | HSD11B1EPHX2 | |
| SCHEMBL4084394 | 0.82 | EPHX2 (0.37) | HSD11B1EPHX2 | |
| SCHEMBL4082735 | 0.75 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL75016 | 0.66 | HSD11B1 (0.37) | HSD11B1EPHX2 | |
| SCHEMBL4081926 | 0.66 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL4084690 | 0.66 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL4083698 | 0.65 | HSD11B1 (0.40) | HSD11B1 | |
| SCHEMBL76738 | 0.64 | EPHX2 (0.36) | HSD11B1EPHX2 | |
| SCHEMBL4078953 | 0.61 | MAPT (0.30) | HSD11B1 | |
| SCHEMBL4083318 | 0.61 | MAPT (0.30) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | claimed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | claimed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |